U.S. Stock Market Moves: GlaxoSmithKline Plunged on October 28 Due to Restructuring Costs, Declining Profits, and Weak Vaccine Performance

GSK October 28 Drop Analysis

Keywords: restructuring costs, profit decline, vaccine weakness

1. On October 28, GSK released its third-quarter results. While revenue and adjusted earnings per share exceeded expectations, attributable profit declined year-on-year. Reported earnings per share dropped from £0.491 to £0.379. Restructuring costs of £328 million dragged total operating profit down by 16% year-on-year.

2. On October 28, GSK disclosed that third-quarter vaccine sales fell by 2% year-on-year, with Shingrix down 5% and Arexvy down 24%. The company expects full-year core earnings per share growth to be at the lower end of its guidance range, citing increased interest expenses as one of the reasons.

(Disclaimer: This content is collected and summarized by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)